A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus

A Gupta; Carmine Monteferrante; D Rasina; G Leitis; CP Randall; JH Tomlinson; A Jirgensons; Wil Goessens; John Hays; AJ O'Neill

doi:10.1128/AAC.02940-15

A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus

A Gupta, Carmine Monteferrante, D Rasina, G Leitis, CP Randall, JH Tomlinson, A Jirgensons, Wil Goessens, John Hays, AJ O'Neill

Medical Microbiology & Infectious Diseases

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

Abstract

GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P-329) within the editing domain of LeuRS.

Original language	Undefined/Unknown
Pages (from-to)	3219-3221
Number of pages	3
Journal	Antimicrobial Agents & Chemotherapy
Volume	60
Issue number	5
DOIs	https://doi.org/10.1128/AAC.02940-15
Publication status	Published - 2016

Research programs

EMC MM-04-28-01

Access to Document

10.1128/AAC.02940-15

Cite this

@article{d7bff2790e324d58a6615746c735d2c6,

title = "A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus",

abstract = "GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P-329) within the editing domain of LeuRS.",

author = "A Gupta and Carmine Monteferrante and D Rasina and G Leitis and CP Randall and JH Tomlinson and A Jirgensons and Wil Goessens and John Hays and AJ O'Neill",

year = "2016",

doi = "10.1128/AAC.02940-15",

language = "Undefined/Unknown",

volume = "60",

pages = "3219--3221",

journal = "Antimicrobial Agents & Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus

AU - Gupta, A

AU - Monteferrante, Carmine

AU - Rasina, D

AU - Leitis, G

AU - Randall, CP

AU - Tomlinson, JH

AU - Jirgensons, A

AU - Goessens, Wil

AU - Hays, John

AU - O'Neill, AJ

PY - 2016

Y1 - 2016

N2 - GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P-329) within the editing domain of LeuRS.

AB - GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P-329) within the editing domain of LeuRS.

U2 - 10.1128/AAC.02940-15

DO - 10.1128/AAC.02940-15

M3 - Article

C2 - 26976861

SN - 0066-4804

VL - 60

SP - 3219

EP - 3221

JO - Antimicrobial Agents & Chemotherapy

JF - Antimicrobial Agents & Chemotherapy

IS - 5

ER -